Phase 2 study of Wee1 inhibitor adavosertib in recurrent uterine carcinosarcoma
In this phase II trial of 9 patients with <i>TP53</i>-mutated UCS, adavosertib demonstrated limited activity. However, future studies of molecular alterations and combinatorial strategies continue to be of interest in UCS with limited treatment options.
Authors
- Cara Mathews (ORCID: https://orcid.org/0000-0001-8461-4568)
- Elizabeth K. Lee (ORCID: https://orcid.org/0000-0001-7533-7853)
- Stephanie Cham (ORCID: https://orcid.org/0000-0003-0621-255X)
- Hannah Sawyer
- Carolyn Krasner
- Alexi A. Wright (ORCID: https://orcid.org/0000-0002-9776-7114)
- Ursula A. Matulonis (ORCID: https://orcid.org/0000-0002-3103-6992)
- Niya Xiong (ORCID: https://orcid.org/0000-0003-2496-9409)
- Nabihah Tayob (ORCID: https://orcid.org/0000-0001-6088-167X)
- Panagiotis A. Konstantinopoulos (ORCID: https://orcid.org/0000-0002-1032-1479)
- Joyce Liu (ORCID: https://orcid.org/0009-0008-4667-6555)
Institutions
- University of California, San Francisco (US)
- Dana-Farber Cancer Institute (US)
- Women & Infants Hospital of Rhode Island (US)
- University of San Francisco (US)
Publication Details
- Journal
- Gynecologic Oncology Reports
- Published
- 2025-06-24
- DOI
- https://doi.org/10.1016/j.gore.2025.101796
- Citations
- 1
- Primary Topic
- Renal and related cancers
- Type
- article
- Field-Weighted Citation Impact
- 0.81